Foster Dykema Cabot & Co. Inc. MA acquired a new position in shares of Baxter International Inc. (NYSE:BAX) during the second quarter, Holdings Channel reports. The institutional investor acquired 3,384 shares of the medical instruments supplier’s stock, valued at approximately $205,000.

Other large investors have also made changes to their positions in the company. Quadrant Capital Group LLC increased its stake in shares of Baxter International by 1.3% in the first quarter. Quadrant Capital Group LLC now owns 2,344 shares of the medical instruments supplier’s stock worth $113,000 after buying an additional 31 shares in the last quarter. Dumont & Blake Investment Advisors LLC boosted its position in Baxter International by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 12,786 shares of the medical instruments supplier’s stock valued at $663,000 after buying an additional 40 shares during the period. Livingston Group Asset Management CO operating as Southport Capital Management boosted its position in Baxter International by 0.3% in the first quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 18,079 shares of the medical instruments supplier’s stock valued at $938,000 after buying an additional 54 shares during the period. Reliance Trust Co. of Delaware boosted its position in Baxter International by 1.1% in the first quarter. Reliance Trust Co. of Delaware now owns 5,743 shares of the medical instruments supplier’s stock valued at $298,000 after buying an additional 63 shares during the period. Finally, Clifford Swan Investment Counsel LLC boosted its position in Baxter International by 0.4% in the first quarter. Clifford Swan Investment Counsel LLC now owns 15,204 shares of the medical instruments supplier’s stock valued at $788,000 after buying an additional 67 shares during the period. 85.08% of the stock is owned by institutional investors and hedge funds.

Shares of Baxter International Inc. (NYSE BAX) opened at 59.84 on Friday. The firm has a market capitalization of $32.61 billion, a price-to-earnings ratio of 36.31 and a beta of 0.66. The stock has a 50 day moving average of $60.89 and a 200-day moving average of $55.35. Baxter International Inc. has a 52 week low of $43.13 and a 52 week high of $63.14.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, topping the consensus estimate of $0.57 by $0.06. Baxter International had a net margin of 8.85% and a return on equity of 14.82%. The company had revenue of $2.61 billion during the quarter, compared to analysts’ expectations of $2.59 billion. During the same quarter in the previous year, the company earned $0.46 EPS. Baxter International’s revenue was up .8% on a year-over-year basis. Analysts expect that Baxter International Inc. will post $2.39 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 2nd. Stockholders of record on Friday, September 1st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Wednesday, August 30th. Baxter International’s dividend payout ratio is 38.79%.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/12/foster-dykema-cabot-co-inc-ma-invests-205000-in-baxter-international-inc-bax.html.

Several research analysts have commented on BAX shares. Zacks Investment Research upgraded shares of Baxter International from a “hold” rating to a “strong-buy” rating and set a $64.00 target price for the company in a research report on Monday, May 1st. UBS AG upped their target price on shares of Baxter International from $57.00 to $62.00 and gave the stock a “neutral” rating in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) restated a “conviction-buy” rating and issued a $71.00 target price on shares of Baxter International in a research report on Tuesday, May 16th. Morgan Stanley upped their target price on shares of Baxter International from $48.00 to $52.00 and gave the stock an “underweight” rating in a research report on Friday, April 28th. Finally, Barclays PLC upped their target price on shares of Baxter International from $64.00 to $70.00 and gave the stock an “overweight” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $65.33.

In other news, Director Carole J. Shapazian sold 2,618 shares of Baxter International stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $57.92, for a total transaction of $151,634.56. Following the completion of the sale, the director now owns 9,848 shares in the company, valued at approximately $570,396.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.05% of the stock is owned by insiders.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.